PF3845 |cas 1196109-52-0|DC Chemicals|Supplier|Price|Buy

PF3845 |cas 1196109-52-0|DC Chemicals|Supplier|Price|Buy

DC Chemicals supplies: PF3845 ,cas: 1196109-52-0,Catalog: DC7611,In stock.

Contact: website: www.dcchemicals.com,

sales@dcchemicals.com,order@dcchemicals.com,info@dcchemicals.com,

Tel: +86-21-58447131;Fax:+86-21-61643258；

Product name: PF3845 , Synonyms: PF-3845,PF 3845 , cas: 1196109-52-0, MW: 456.46, Molecule Formula: C24H23F3N4O2

PF3845 

, cas 1196109-52-0, Purity>98%, In stock,from DC Chemicals. PF-3845 is a potent, selective and irreversible FAAH inhibitor with Ki of 230 nM, showing negligible activity against FAAH2.PF-3845 selectively inhibits FAAH by carbamylating FAAH's serine nucleophile. [1] PF-3845 treated mice (10 mg/kg, i.p.) shows rapid and complete inactivation of FAAH in the brain, as judged by competitive activity-based protein profiling (ABPP) with the serine hydrolase-directed probe fluorophosphonate (FP)-rhodamine. PF-3845 shows a long duration of action up to 24 hour. PF-3845-treated mice also shows dramatic (>10-fold) elevation in brain levels of AEA and other NAEs (N-pamitoyl ethanolamine [PEA] and N-oleoyl ethanolamine [OEA]). FAAH is AEA-degrading enzyme fatty acid amide hydrolase. PF-3845 (1–30 mg/kg, oral administration [p.o.]) causes a dose dependent inhibition of mechanical allodynia with a minimum effective dose (MED) of 3 mg/kg (rats are analyzed at 4 hour post dosing with PF-3845). At higher doses (10 and 30 mg/kg), PF-3845 inhibits pain responses to an equivalent, if not greater, degree than the nonsteroidal anti-inflammatory drug naproxen (10mg/kg, p.o.). [1] PF-3845 (10 mg/kg, i.p.) significantly reverses LPS-induced tactile allodynia, but doesn't modify paw withdrawal thresholds in the saline-injected paw. [2]

PF-3845 selectively inhibits FAAH by carbamylating FAAH's serine nucleophile. [1] PF-3845 treated mice (10 mg/kg, i.p.) shows rapid and complete inactivation of FAAH in the brain, as judged by competitive activity-based protein profiling (ABPP) with the serine hydrolase-directed probe fluorophosphonate (FP)-rhodamine. PF-3845 shows a long duration of action up to 24 hour. PF-3845-treated mice also shows dramatic (>10-fold) elevation in brain levels of AEA and other NAEs (N-pamitoyl ethanolamine [PEA] and N-oleoyl ethanolamine [OEA]). FAAH is AEA-degrading enzyme fatty acid amide hydrolase. PF-3845 (1–30 mg/kg, oral administration [p.o.]) causes a dose dependent inhibition of mechanical allodynia with a minimum effective dose (MED) of 3 mg/kg (rats are analyzed at 4 hour post dosing with PF-3845). At higher doses (10 and 30 mg/kg), PF-3845 inhibits pain responses to an equivalent, if not greater, degree than the nonsteroidal anti-inflammatory drug naproxen (10mg/kg, p.o.). [1] PF-3845 (10 mg/kg, i.p.) significantly reverses LPS-induced tactile allodynia, but doesn't modify paw withdrawal thresholds in the saline-injected paw. [2]For the detailed information of PF3845 

, the solubility of PF3845 

 in water, the solubility of PF3845 

 in DMSO, the solubility of PF3845 

 in PBS buffer, the animal experiment (test) of  PF3845 

, the cell expriment (test) of PF3845 

, the in vivo, in vitro and clinical trial test of PF3845 

, the EC50, IC50,and Affinity of PF3845 

, Please contact DC Chemicals.